While urological malignancies have traditionally been linked with androgen signaling, recent studies reveal a complex interplay where estrogen receptors-ERα, ERβ, and GPER-modulate critical cellular processes such as proliferation, apoptosis, and metastasis in these cancers. Here, ESR2 is linked to cancer.